You did the reading. You watched the science move on from the old headlines, and you are done being told that broken sleep and hot flashes are just the price of being a woman in your fifties. Here is what an independent provider actually looks at when a woman who is fully through menopause wants a real plan instead of a shrug.

First, a word about the fear you were handed

Most women who are cautious about hormones today are reacting to the first reports from the Women's Health Initiative (WHI) in the early 2000s. Those early headlines were broad. The more careful, later analyses showed that risk and benefit depend heavily on *who* is being treated, *how old* they are, *how far* from their final period they are, and *which* hormones and routes are used [1][2]. The North American Menopause Society now frames hormone therapy decisions around individual risk, timing, and symptoms rather than a one-size-fits-all warning [2]. That is the modern, balanced ground a good provider stands on.

This article is educational and is not medical advice. A prescription is never guaranteed; it is a decision made by an independent licensed provider after reviewing your history, your goals, and your labs.

The timing conversation: why "how long ago" matters

Providers pay attention to your age and how many years you are past your final menstrual period because the research clusters benefit and risk differently across that window. Analyses of the WHI and other data describe a more favorable risk profile for women who begin therapy closer to menopause and at younger ages, compared with starting many years later [1][2]. This is sometimes called the "timing hypothesis." It does not mean a fixed door slams shut on a birthday — it means the conversation is individualized, and your specific timeline is part of the math.

Hormonal markers a provider may review

Menopause is usually diagnosed clinically — by your symptoms and the pattern of your periods — not by a single lab. But specific hormonal markers can help confirm the picture and rule out other causes of fatigue, fog, and poor sleep.

  • FSH (follicle-stimulating hormone). After menopause, FSH typically runs persistently high because the ovaries are no longer responding [3]. It helps confirm menopausal status when the picture is unclear.
  • Estradiol. The main estrogen of the reproductive years falls to low levels after menopause [3]. It is one piece of context, not a target to "correct" to a number.
  • TSH (thyroid-stimulating hormone). Thyroid disease can mimic menopause symptoms — fatigue, brain fog, weight and mood changes — so providers commonly check it to avoid blaming everything on hormones [4].

The goal of these labs is not to chase a perfect number. It is to understand your baseline and exclude look-alike conditions before any plan is considered.

Cardiovascular markers: the heart half of the equation

After menopause, cardiovascular risk profiles often shift, and heart disease is the leading cause of death in women [5]. Because some hormone therapy decisions interact with cardiovascular risk, a provider typically reviews:

  • Blood pressure. A foundational, modifiable risk factor tracked at every step [5].
  • Lipid panel — total cholesterol, LDL-C, HDL-C, and triglycerides. The American Heart Association and ACC use these to estimate overall cardiovascular risk [5].
  • Fasting glucose and/or A1c. Screens for diabetes and prediabetes, which independently raise cardiovascular risk [5].
  • Overall risk estimation. Providers often combine these with age, smoking status, and history using a pooled risk estimate to frame the benefit–risk discussion before any hormone conversation [5].

The route of estrogen can also be part of the discussion — for example, transdermal versus oral preparations are studied differently with respect to certain clotting-related risks — but those are clinical judgments an independent provider makes with your full history, not something to self-prescribe.

The order a provider tends to work in (no dosing)
1History & symptomsTimeline since final period
2Labs reviewedHormonal, cardiac, bone
3Benefit–risk discussionIndividualized framing
4Shared decisionPlan, if any, is the provider's call

Source: [2] The 2022 Hormone Therapy Position Statement of The North American Menopause Society, [3] Menopause — StatPearls (NIH/NCBI Bookshelf), [5] 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, [6] Osteoporosis Overview — NIH Osteoporosis and Related Bone Diseases National Resource Center

Bone markers: the quiet risk that builds for years

Estrogen helps maintain bone. The accelerated bone loss around and after menopause is well documented, and it is largely silent until a fracture happens [6]. So bone health is a central part of the picture:

  • DXA bone density (T-score). A dual-energy X-ray absorptiometry scan reports a T-score. The World Health Organization defines a T-score of −1.0 to −2.5 as low bone mass (osteopenia) and −2.5 or lower as osteoporosis [6][7]. The U.S. Preventive Services Task Force recommends screening for osteoporosis in women 65 and older, and earlier for those with elevated risk [7].
  • Vitamin D (25-hydroxyvitamin D) and calcium. Reviewed in the context of bone health and metabolism [6].
  • Fracture-risk factors. Family history, prior fractures, body weight, and certain medications all feed into how seriously bone protection is weighed [6].

For a busy woman who needs her body to keep up with a demanding job, bone is not an abstraction — it is the difference between a plan that protects the next thirty years and one that only chases tonight's hot flash.

DXA T-score: how bone density is classified
Osteoporosis ≤-2.5Low bone mass (osteopenia) ≤-1Normal ≤1

T-score · marker = Osteoporosis threshold

Source: [6] Osteoporosis Overview — NIH Osteoporosis and Related Bone Diseases National Resource Center, [7] Osteoporosis to Prevent Fractures: Screening — US Preventive Services Task Force Recommendation

Putting it together

Notice the pattern: hormonal markers confirm where you are and rule out mimics; cardiovascular markers frame safety and overall risk; bone markers protect your long game. None of these is a green light or a red light by itself. A provider reads them *together*, alongside your symptoms, your timeline since menopause, and what you actually want out of the next decade. That is the difference between "tough it out" and a real plan.

If a provider does consider hormone therapy, options span FDA-approved products in various forms and, in some cases, compounded preparations. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. Which path — if any — fits you is a clinical decision, not a marketing one.

Markers grouped by what they help a provider see
FSH · Estradiol · TSHHormonal / mimic checkConfirm status, rule out look-alikes
BP · Lipids · GlucoseCardiovascularFrame overall risk
DXA · Vit D · CalciumBoneProtect the long game

Source: [3] Menopause — StatPearls (NIH/NCBI Bookshelf), [5] 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease, [6] Osteoporosis Overview — NIH Osteoporosis and Related Bone Diseases National Resource Center

Where Velri fits

Velri is a technology and coordination company — not a medical practice. We help organize the practical steps so you are not chasing them alone: coordinating lab work, connecting you with an independent, licensed provider who reviews your markers and history with current, balanced framing, and — *only if that provider prescribes* — coordinating with an independent licensed pharmacy. Care is provided by the independent provider groups; medications are dispensed by independent pharmacies. We don't promise a prescription or an outcome. We make it easier to have the modern, informed conversation you came looking for. This article is educational and is not a substitute for individualized medical advice from your provider.